Research programme: catalytic antioxidants - Aeolus Pharmaceuticals
Alternative Names: AEOL-10113; AEOL-11207Latest Information Update: 04 Nov 2017
At a glance
- Originator Duke University; National Jewish Medical and Research Center
- Developer Aeolus Pharmaceuticals Inc
- Class Porphyrins; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Parkinson's disease; Radiation injuries
- Discontinued Asthma; Bronchitis; Cancer; Chronic obstructive pulmonary disease; Ischaemic heart disorders; Liver disorders; Reperfusion injury; Rheumatoid arthritis; Stomatitis; Stroke; Type 1 diabetes mellitus; Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Epilepsy in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries(Prevention) in USA